Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Avid Bioservices Inc CDMO

Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company provides a range of services from process development to Current Good Manufacturing Practices (CGMP) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. It operates in a single segment, which is contract manufacturing and development services... see more

NDAQ:CDMO - Post Discussion

Avid Bioservices Inc > Biotech/Pharma Contract Service Provider Avid Bioservices Se
View:
Post by whytestocks on Mar 07, 2024 5:30pm

Biotech/Pharma Contract Service Provider Avid Bioservices Se

News; $CDMO Biotech/Pharma Contract Service Provider Avid Bioservices Sees Lower Than Expected Q3 Sales, Sticks To Annual Guidance | BenzingaWednesday, Avid Bioservices Inc (NASDAQ:CDMO) reported preliminary revenues for the third quarter of fiscal 2024 of $33.8 million, repres...CDMO - Biotech/Pharma Contract Service Provider Avid Bioservices Sees Lower Than Expected Q3 Sales, Sticks To Annual Guidance | Benzinga
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities